• Title/Summary/Keyword: Growth Associated Hormone

Search Result 126, Processing Time 0.025 seconds

Growth hormone treatment and risk of malig­nancy

  • Chae, Hyun-Wook;Kim, Duk-Hee;Kim, Ho-Seong
    • Clinical and Experimental Pediatrics
    • /
    • v.58 no.2
    • /
    • pp.41-46
    • /
    • 2015
  • Growth hormone (GH) treatment has been increasingly widely used for children with GH deficiencies as the survival rate of pediatric patients with malignancies has increased. Both GH and insulin-like growth factor-I have mitogenic and antiapoptotic activity, prompting concern that GH treatment may be associated with tumor development. In this review, the authors examined the relationship between GH treatment and cancer risk in terms of de novo malignancy, recurrence, and secondary neoplasm. Although the results from numerous studies were not entirely consistent, this review of various clinical and epidemiological studies demonstrated that there is no clear evidence of a causal relationship between GH treatment and tumor development. Nonetheless, a small number of studies reported that childhood cancer survivors who receive GH treatment have a small increased risk of developing de novo cancer and secondary malignant neoplasm. Therefore, regular follow-ups and careful examination for development of cancer should be required in children who receive GH treatment. Continued surveillance for an extended period is essential for monitoring long-term safety.

Effect of KiFAY on Performance, Insulin-like Growth Factor-1, and Thyroid Hormones in Broilers

  • Kini, Amit;Fernandes, Custan;Suryawanshi, Dayaram
    • Asian-Australasian Journal of Animal Sciences
    • /
    • v.29 no.10
    • /
    • pp.1451-1457
    • /
    • 2016
  • A comparative study was performed to investigate the efficacy of KiFAY as a feed additive on performance parameters, thyroid, and pancreatic hormone levels in broilers. Ninety birds (Vencobb 400) were randomly divided into three groups viz., Control (no DL-methionine supplementation), Treatment1 (containing added DL-methionine) and Treatment 2 (containing KiFAY and without DL-methionine supplementation). The performance parameters (weekly body weight, body weight gain, feed intake, and feed consumption ratio) were recorded and calculated during the whole study of 4 weeks. Analyses of insulin and insulin-like growth factor (IGF 1), triiodothyronine (T3), thyroxine (T4) and thyroid stimulating hormone (TSH) were performed at the end of the study. The results show that birds on supplementation of KiFAY performed significantly (p<0.001) better than other treatments. The weekly body weight, body weight gain, feed in-take and feed consumption ratio improved in KiFAY treated birds. The study found an increase in insulin and IGF1 levels (p<0.001) in KiFAY compared with the other treatments. Serum T3, T4, and TSH levels in the Treatment 2 were higher than other treatments (p<0.001). The KiFAY supplementation was able to improve performance with associated responses at a hormonal level in broilers.

Growth hormone therapy in patients with Noonan syndrome

  • Seo, Go Hun;Yoo, Han-Wook
    • Annals of Pediatric Endocrinology and Metabolism
    • /
    • v.23 no.4
    • /
    • pp.176-181
    • /
    • 2018
  • Noonan syndrome (NS) is an autosomal dominant disorder that involves multiple organ systems, with short stature as the most common presentation (>70%). Possible mechanisms of short stature in NS include growth hormone (GH) deficiency, neurosecretory dysfunction, and GH resistance. Accordingly, GH therapy has been carried out for NS patients over the last three decades, and multiple studies have reported acceleration of growth velocity (GV) and increase of height standard deviation score (SDS) in both prepubertal and pubertal NS patients upon GH therapy. One year of GH therapy resulted in almost doubling of GV compared with baseline; afterwards, the increase in GV gradually decreased in the following years, showing that the effect of GH therapy wanes over time. After four years of GH therapy, ~70% of NS patients reached normal height considering their age and sex. Early initiation, long duration of GH therapy, and higher height SDS at the onset of puberty were associated with improved final height, whereas gender, dosage of GH, and the clinical severity did not show significant association with final height. Studies have reported no significant adverse events of GH therapy regarding progression of hypertrophic cardiomyopathy, alteration of metabolism, and tumor development. Therefore, GH therapy is effective for improving height and GV of NS patients; nevertheless, concerns on possible malignancy remains, which necessitates continuous monitoring of NS patients receiving GH therapy.

Analysis of Coat Color Changes and Hormone Levels in Korean Brindle Cattle (칡소의 모색 발현과 호르몬 변화와의 상관관계 분석 연구)

  • Lee, Hae-Lee;Park, Jae-Hee;Kim, Yong-Su;Kim, Jong Gug
    • Journal of Embryo Transfer
    • /
    • v.30 no.1
    • /
    • pp.65-71
    • /
    • 2015
  • The aim of this study was to determine the relationship between the coat color appearance of Korean brindle cattle and the changes of relevant hormone levels that may affect the hair pigmentation during different stages of growth and maturation. In mature cattle, levels of both ACTH and DHEA in Korean brindle cattle with brown color were significantly higher than those with black color (p<0.05). Levels of ${\alpha}$-MSH in Korean brindle cattle with whole brindle ($${\geq_-}50%$$) color were significantly higher than those with brown color (p<0.05). In calves of Korean brindle cattle at 2 to 6 months, the concentration of estradiol was significantly higher in calves with whole brindle color than those with part brindle color (p<0.05), when the coat color was confirmed. After 6 month of coat color confirmation, levels of testosterone and ACTH increased in calves with part brindle color and were significantly higher than those with whole brindle color (p<0.05). In calves of Korean brindle cattle at 1 or 2 months, there were no significant differences in hormone levels of estradiol, ACTH, DHEA and ${\alpha}$-MSH between the calves with brindle color and brown color, except estradiol before brindle color appearance. Changes of relevant hormone levels at different stage of growth and maturation may affect the pigmentation of coat during the development of cattle. In addition to the current study correlating the different coat colors with relevant hormone levels, investigation of the coat color associated genes expressed in Korean brindle cattle may further clarify the mechanisms of coat color changes during their development.

Rat Gonadotropes and Somatotropes Express Growth Hormone Releasing Hormone Gene in the Pituitary (흰쥐 뇌하수체 Gonadotropes와 Somatotropes에서의 Growth Hormone Releasing Hormone 유전자 발현)

  • 이성호
    • Development and Reproduction
    • /
    • v.2 no.2
    • /
    • pp.189-196
    • /
    • 1998
  • Several lines of evidence indicate that some neuropeptides classically associated hypothalamus have been found in pituitary gland, suggesting the existence of local regulation of pituitary function. Among the hypothalamic releasing hormones, genes for TRH and GnRH are expressed in the rat anterior pituitary gland. The present study was carried out to investigate the expression of the GHRH gene in rat anterior pituitary and the pituitary-derived cell lines. The presence of GHRH transcripts in pituitary tissue was shown by 3'rapid amplification of cDNA end (3'-RACE) analysis. In reverse transcription-polymerase chain reaction (RT-PCR) study, GHRH cDNA fragments were amplified from two pituitary-derived cell lines, $\alpha$T3 cells originated from mouse gonadotrope and GH3 cells from rat somatolactotrope. Immunoreactive GHRH was detected in large and medium-sized pituitary cells by immunocytochemistry. Significant amounts of GHRH-like molecules were found in the GH3 cell extracts. In RNase protection assay, the level of pituitary GHRH mRNA was augmented by ovariectomy. These results demonstrate that GHRH gene is expressed in the rat gonadotropes and somatotropes, and suggest that the pituitary GHRH could be participated in the paracrine and/or autocrine regulation of cell proliferation, as well as promoting growth hormone secretion.

  • PDF

Association of GHRH, H-FABP and MYOG Polymorphisms with Economic Traits in Pigs

  • Cho, Eun Seok;Park, Da Hye;Kim, Byeong-Woo;Jung, Won Youg;Kwon, Eun Jung;Kim, Chul Wook
    • Asian-Australasian Journal of Animal Sciences
    • /
    • v.22 no.3
    • /
    • pp.307-312
    • /
    • 2009
  • The study of candidate genes is an important tool to identify genes associated with economic traits. Three genes were selected to study the association between polymorphism and economic traits and breed of pigs. Growth hormone releasing hormone (GHRH) takes part in growth metabolism and is one of the candidate genes known to be highly associated with economic traits in pigs. Heart fatty acid-binding protein (H-FABP) is related to back fat thickness and intramuscular fat (IMF) content, and myogenin (MYOG) is associated with the amount of growth rate and lean yield in pigs. By PCR-RFLP analysis, the association between the genotypes of the three genes and the average daily gain, back fat thickness, feed conversion, body length and meat percent in 352 pigs (112 Duroc pigs, 132 Landrace pigs and 108 Yorkshire pigs) were analyzed. GHRH polymorphisms showed differences depending on breed (p<0.01) and were associated with meat percent. H-FABP polymorphisms also showed significant differences among breeds and sex (p<0.01), and were highly associated with average daily gain, feed conversion and back fat thickness (p<0.01) and even showed an association with meat percent (p<0.05). However, the MYOG gene showed no significant effect in this study. These results reconfirmed that GHRH and H-FABP are potential major genes or markers for economic traits.

The Growth-promoting Effect of Tetrabasic Zinc Chloride is Associated with Elevated Concentration of Growth Hormone and Ghrelin

  • Zhang, Bingkun;Guo, Yuming
    • Asian-Australasian Journal of Animal Sciences
    • /
    • v.21 no.10
    • /
    • pp.1473-1478
    • /
    • 2008
  • An experiment was conducted to investigate the mechanism for the effect of tetrabasic zinc chloride (TBZC) in enhancing growth performance of weanling piglets. Gut-brain peptides play an important role in the regulation of growth and appetite in animals. This study evaluated the effects of TBZC on blood concentrations of growth hormone (GH), ghrelin, insulin-like growth factor-I (IGF-I), cholecystokinin (CCK) and neuropeptide Y (NPY). Seventy-two weanling piglets (Landrace$\times$Large White) with an initial body weight (BW) of $6.7{\pm}0.16kg$ and aged $24{\pm}1days$ were assigned to three dietary treatments: i) control diet without TBZC supplement, ii) the control diet supplemented with 2,000 mg Zn from TBZC/kg and iii) TBZC-supplemented diet pair-fed with respect to the control diet. Each treatment had six replications (pens) of four piglets. At the end of a 14-d experimental period, piglets were weighed and feed consumption was measured, and blood samples were collected for assays of GH, ghrelin, IGF-I, CCK and NPY concentrations. The inclusion of TBZC in the diet increased average daily gain (p<0.01), average daily feed intake (p<0.05), and feed conversion ratio (p<0.05). Pair-fed piglets had higher ADG, and lower FCR than (p<0.05) Control piglets. Supplementation of the diet with TBZC increased (p<0.05) serum GH and plasma ghrelin levels in weanling piglets, but did not affect (p>0.05) serum IGF-I and plasma NPY and CCK concentrations. Pair-fed piglets had lower (p<0.05) serum GH levels than TBZC-supplemented piglets, but did not (p>0.05) differ from Control piglets. These data indicated that TBZC elevated the concentration of ghrelin and GH. This observation may partly explain the beneficial effects of TBZC on growth performance of weanling piglets.

Effect of Hormone Therapy on Long-term Outcomes of Patients with Human Epidermal Growth Factor Receptor 2-and Hormone Receptor-Positive Metastatic Breast Cancer: Real World Experience in China

  • Du, Feng;Yuan, Peng;Wang, Jia-Yu;Ma, Fei;Fan, Ying;Luo, Yang;Xu, Bing-He
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.16 no.3
    • /
    • pp.903-907
    • /
    • 2015
  • Background: Among human epidermal growth factor receptor 2 (HER2)-positive breast cancer, more than half are also hormone receptor (HR)-positive. Although HR is a predictive factor for the efficacy of hormone therapy, there are still some uncertainties in regard to the effects on patients with HR-positive and HER2-positive metastatic breast cancers due to the potential resistance to hormone therapy caused by co-expression of HR and HER2. There are no clinical trials directly comparing the efficacy of hormonal therapy with chemotherapy. Materials and Methods: To examine the real-world effect of hormone therapy on patients with HR-positive and HER2-positive metastatic breast cancers, a cross-sectional study of a representative sample of the Chinese population was conducted. The study included 113 patients who received first-line and second-line palliative treatment between 2005 and 2010 in the Cancer Institute and Hospital, Chinese Academy of Medical Science. The effect of hormone therapy on overall survival (OS) was studied. Results: The patients who received hormone therapy (n=51) had better overall survival in contrast to those who received chemotherapy with anti-HER2 therapy (n=62) in first- or second-line treatment. The difference was of borderline statistical significance (51.8m vs 31.9m, p=0.065). In addition, the effect of hormone therapy did not differ significantly with other prognostic factors, including age (${\leq}50$ years or >50 years), disease free survival (${\geq}2$ years or < 2 years) and site of metastasis (visceral or bone/soft tissue). On multivariate analysis, administration of hormone therapy was associated with a trend toward a favorable prognosis (p=0.148, HR=0.693, 95%CI 0.422-1.139). Age more than 50 years was the sole independent harmful prognostic factor (p<0.001, HR=2.797, 95%CI 1.676-4.668). Conclusions: Our data suggest that hormonel therapy may improve outcomes of the patients with ER-positive and HER2-positive metastatic breast cancer.

Tyrosine phosphorylation as a signaling component for plant improvement

  • Park, Youn-Il;Yang, Hyo-Sik;Oh, Man-Ho
    • Journal of Plant Biotechnology
    • /
    • v.42 no.4
    • /
    • pp.277-283
    • /
    • 2015
  • Plant genome analyses, including Arabidopsis thaliana showed a large gene family of plant receptor kinases with various extracellular ligand-binding domain. Now intensively studies to understand physiological and cellular functions for higher plant receptor kinases in diverse and complex biological processes including plant growth, development, ligands perception including steroid hormone and plant-microbe interactions. Brassinosteroids (BRs) as a one of well know steroid hormone are plant growth hormones that control biomass accumulation and also tolerance to many biotic and abiotic stress conditions and hence are of relevance to agriculture. BRI1 receptor kinase, which is localized in plasma membrane in the cell sense BRs and it bind to a receptor protein known as BRASSINOSTEROID INSENSITIVE 1 (BRI1). Recently, we reported that BRI1 and its co-receptor, BRI1-ASSOCIATED KINASE (BAK1) autophosphorylated on tyrosine residue (s) in vitro and in vivo and thus are dual-specificity kinases. Other plant receptor kinases are also phosphorylated on tyrosine residue (s). Post-translational modifications (PTMs) can be studied by altering the residue modified by directed mutagenesis to mimic the modified state or to prevent the modification. These approaches are useful to not only characterize the regulatory role of a given modification, but may also provide opportunities for plant improvement.

Endoscopic Decompression for Optic Neuropathy in McCune-Albright Syndrome

  • Noh, Jung-Hoon;Kong, Doo-Sik;Seol, Ho Jun;Shin, Hyung Jin
    • Journal of Korean Neurosurgical Society
    • /
    • v.56 no.3
    • /
    • pp.281-283
    • /
    • 2014
  • McCune-Albright syndrome (MAS) is characterized by a triad of poly/monostotic fibrous dysplasia, caf$\acute{e}$-au-lait macules and hyperfunctioning endocrinopathies including human growth hormone excess. Acromegaly as a manifestation of endocrine hyperfunction with MAS is uncommon. Surgical excision may be challenging due to the associated severe fibrous dysplasia of the skull base. Through the endoscopic procedures, we treated a case of MAS presenting with compressive optic neuropathy due to fibrous dysplasia and acromegaly caused by growth hormone secreting pituitary adenoma. We reviewed the literature on GH excess in MAS to highlight its surgical and medical challenges.